Midlothian firm lands $400,000 Australian biomedical deal

Arrayjet will work with the Institute of Glycomics to develop the next generation of drugs and vaccines with the help of its state-of-the-art printing technology 

Arrayjet, the Midlothian-based microarray instrumentation company, has secured a $400,000AUD contract with one of Australia’s flagship biomedical research institutes.
It has been awarded the contract by the Institute for Glycomics at Griffith University, which houses some of Australia’s most renowned research groups in developing the next generation of drugs and vaccines to fight diseases of global significance and impact, to provide the most advanced instrumentation printing technology available for the throughput and rapid printing of ‘glycan’ – a complex sugar molecule – arrays.
According to those in-the-know, glycans are present on the surface of all cells and are responsible for a variety of biological functions in humans and micro-organisms such as cell to cell communication.
Arrayjet says this addition will complement the Institute’s existing state-of-the-art instrumentation, and help make its bio-analytical facility a world-leader in glycomics research, analysis and technology development.
The introduction of glycan array-based technology has advanced the field of biological glycomics analysis.
Arrayjet says this powerful tool helps academics and researchers understand how glycans relate to particular biological functions. A
It claims array-based technologies provide two related benefits, the incredible efficiency of sample use for analysis combined with achieving high-throughput parallel compound characterisation.
Dr Chris Davis, general manager at the Institute for Glycomics, said: “As an established world-leader in glycomics translational research, we are delighted to work with Arrayjet to further build translational capacity in our state-of-the-art glyco-bioanalytical facility.
“The speed, spot quality and superb batch-to-batch reproducibility of the Marathon Argus provides us with the reassurance we need to manufacture quality commercial glycoarrays for industry and academia.
“Furthermore, being in a sub-tropical environment here in Queensland, it was imperative that we have exceptional temperature and humidity control.
“Arrayjet was able to offer both dehumidification and humidification in order to minimise the effect during the year, so we never have a need for downtime, which is vitally important for the seamless continuity required within our operations.”
Meanwhile, the Institute for Glycomics is working with Arrayjet to provide life science companies throughout the Asia-Pacific a consulting service based on Arrayjet Advance technology.
It says the service promises fast, reproducible and precision-accurate microarray analytics through Arrayjet’s novel inkjet technology and instrumentation processes for a broad spectrum of diagnostic applications, tailored to suit individual needs.
Iain McWilliam, CEO of Arrayjet, said: “The Institute for Glycomics is at the cutting edge of this complex technology and we are delighted they have chosen us to partner with them at this exciting phase of their development.
“The Marathon Argus will provide the means to effect fast and accurate microarray production giving them complete quality assurance and confidence in their products.  What’s more, we are building a solid customer based across the Asia Pacific Rim and for an SME with its headquarters in Midlothian, Scotland, we are delighted with our international reach and impact.”
Sponsored by